Literature DB >> 7378256

Blood plasma binding of acebutolol and diacetolol in man.

T J Coombs, C J Coulson, V J Smith.   

Abstract

1 Acebutolol or diacetolol were added to fresh human plasma in varying concentrations and their extent of binding at 25 degrees C measureed by an equilibrium dialysis technique. 2 The extent of binding for both compounds was shown to be very low, being 11-19% for acebutolol and 6-9% for diacetolol. 3 Partition coefficients were measured in an n- octanol/phosphate buffer (0.05M, pH 7.4) solvent system. For a cebutolol, P = 0.62 and for diacetol, P = 0.08. 4 The very low plasma binding is in accord with the hydrophilic partition coefficients of these compounds.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378256      PMCID: PMC1429991          DOI: 10.1111/j.1365-2125.1980.tb01067.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Drug-albumin binding.

Authors:  W E Lindup
Journal:  Biochem Soc Trans       Date:  1975       Impact factor: 5.407

2.  Influence of binding on the toxicity of bilirubin.

Authors:  G B Odell
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

3.  Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration.

Authors:  H Kurz; H Trunk; B Weitz
Journal:  Arzneimittelforschung       Date:  1977-07

4.  Binding of adrenergic beta-receptor antagonists to human serum albumin.

Authors:  C Appelgren; K O Borg; R Elofsson; K A Johansson
Journal:  Acta Pharm Suec       Date:  1974-09

5.  Equilibrium dialysis: a new approach.

Authors:  T J Coombs; C J Coulson
Journal:  Biochem Soc Trans       Date:  1978       Impact factor: 5.407

6.  Acebutolol disposition after intravenous administration.

Authors:  P J Meffin; R A Winkle; F A Peters; D C Harrison
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

7.  Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man.

Authors:  P F Meffin; S R Harapat; D C Harrison
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-09

8.  A randomized crossover comparison of acebutolol and methyldopa in the treatment of mild to moderate essential hypertension.

Authors:  A N Chatterji
Journal:  Curr Med Res Opin       Date:  1978       Impact factor: 2.580

9.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

10.  Suppression of premature ventricular contractions by acebutolol.

Authors:  A H Gradman; R A Winkle; J W Fitzgerald; P J Meffin; J Stoner; P A Bell; D C Harrison
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

  10 in total
  5 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

2.  The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva.

Authors:  R Zaman; D B Jack; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 3.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

4.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Authors:  P H Hinderling; O Schmidlin; J K Seydel
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

5.  Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats.

Authors:  M Piquette-Miller; F Jamali
Journal:  Agents Actions       Date:  1992-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.